Literature DB >> 12794389

Combination therapy of donepezil and vitamin E in Alzheimer disease.

Emily T Klatte1, Douglas W Scharre, Haikady N Nagaraja, Rebecca A Davis, David Q Beversdorf.   

Abstract

A retrospective chart review was performed on 130 patients from the Ohio State University Memory Disorders Clinic to examine the long-term effects of combination therapy with donepezil and vitamin E on patients with Alzheimer disease. Subjects were included if they met National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer's Disease and Related Disorders Association criteria for probable Alzheimer disease, had taken at least 5 mg donepezil and at least 1000 U vitamin E daily, had at least a 1-year follow-up while continuing these medications, and had a Mini-Mental State Examination score of 10-24. The Mini-Mental State Examination was then recorded annually thereafter. These data were compared with the Consortium to Establish a Registry for Alzheimer's Disease database for patients collected prior to the availability of these treatment options. Patients declined at a significantly lower rate as compared with the Consortium to Establish a Registry for Alzheimer's Disease data. The long-term combination therapy of donepezil and vitamin E appears beneficial for patients with Alzheimer disease. Future prospective studies would be needed to compare combination treatment to vitamin E and donepezil alone.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12794389     DOI: 10.1097/00002093-200304000-00010

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  9 in total

Review 1.  Combination therapy in Alzheimer's disease: a review of current evidence.

Authors:  Beate Schmitt; Tanja Bernhardt; Hans-Juergen Moeller; Isabella Heuser; Lutz Frölich
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 2.  The effects of twenty-one nutrients and phytonutrients on cognitive function: A narrative review.

Authors:  John E Lewis; Jillian Poles; Delaney P Shaw; Elisa Karhu; Sher Ali Khan; Annabel E Lyons; Susana Barreiro Sacco; H Reginald McDaniel
Journal:  J Clin Transl Res       Date:  2021-08-04

3.  Insulin in central nervous system: more than just a peripheral hormone.

Authors:  Ana I Duarte; Paula I Moreira; Catarina R Oliveira
Journal:  J Aging Res       Date:  2012-02-21

4.  Donepezil in Alzheimer's disease: an evidence-based review of its impact on clinical and economic outcomes.

Authors:  Joanne Knowles
Journal:  Core Evid       Date:  2006-03-31

Review 5.  AChE Inhibition-based Multi-target-directed Ligands, a Novel Pharmacological Approach for the Symptomatic and Disease-modifying Therapy of Alzheimer's Disease.

Authors:  Yu Wang; Hao Wang; Hong-zhuan Chen
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

6.  Discontinuation Rate of Newly Prescribed Donepezil in Alzheimer's Disease Patients in Asia.

Authors:  Kee Hyung Park; YoungSoon Yang; Christopher Chen; Yong S Shim; Jacqueline C Domingueze; Chan Nyoung Lee; Kyunghun Kang; Hee Jin Kim; Seul Ki Jeong; Jee Hyang Jeong; Zhen Hong; Soo Jin Yoon; Zhen Xin Zhang; Eun Joo Kim; Jae Won Jang; Yansheng Li; Yun Xu; Yu Te Lin; Qiumin Qu; Chaur Jong Hu; Chih Ho Chou; Dongsheng Fan; Nagaendran Kandiah; Yuan Han Yang; Chi Ieong Lau; Leung Wing Chu; Huali Wang; San Jung; Seong Hye Choi; SangYun Kim
Journal:  J Clin Neurol       Date:  2021-07       Impact factor: 3.077

7.  Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics.

Authors:  Ramón Cacabelos
Journal:  Neuropsychiatr Dis Treat       Date:  2007-06       Impact factor: 2.570

8.  Vitamin E therapy prevents the accumulation of congophilic amyloid plaques and neurofibrillary tangles in the hippocampus in a rat model of Alzheimer's disease.

Authors:  Mehrdad Jahanshahi; Emsehgol Nikmahzar; Ali Sayyahi
Journal:  Iran J Basic Med Sci       Date:  2020-01       Impact factor: 2.699

9.  Sulphonamides incorporating 1,3,5-triazine structural motifs show antioxidant, acetylcholinesterase, butyrylcholinesterase, and tyrosinase inhibitory profile.

Authors:  Nabih Lolak; Mehmet Boga; Muhammed Tuneg; Gulcin Karakoc; Suleyman Akocak; Claudiu T Supuran
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.